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Background. HIV-infected women are disproportionately burdened by gynaecological complications, psychological disorders, and
certain sexually transmitted infections that may not be adequately addressed by HIV-specific care. We estimate the prevalence
and covariates of women’s health care (WHC) utilization among harder-to-reach, treatment-experienced HIV-infected women in
British Columbia (BC), Canada. Methods. We used survey data from 231 HIV-infected, treatment-experienced women enrolled
in the Longitudinal Investigations into Supportive and Ancillary Health Services (LISA) study, which recruited harder-to-reach
populations, including aboriginal people and individuals using injection drugs. Independent covariates of interest included
sociodemographic, psychosocial, behavioural, individual health status, structural factors, and HIV clinical variables. Logistic
regression was used to generate adjusted estimates of associations between use of WHC and covariates of interest. Results. Overall,
77% of women reported regularly utilizing WHC. WHC utilization varied significantly by region of residence (P value < 0.01).
In addition, women with lower annual income (AOR (95%CI) = 0.14 (0.04–0.54)), who used illicit drugs (AOR (95%CI) = 0.42
(0.19–0.92)) and who had lower provider trust (AOR (95%CI) = 0.97 (0.95–0.99)), were significantly less likely to report using
WHC. Conclusion. A health service gap exists along geographical and social axes for harder-to-reach HIV-infected women in BC.
Women-centered WHC and HIV-specific care should be streamlined and integrated to better address women’s holistic health.
1. Introduction
More than 30 years into the global HIV/AIDS epidemic, 33.3
million people worldwide are currently living with HIV, of
whom more than 50% are women and girls [1]. In Canada,
the proportion of women among newly reported HIV cases
has increased from less than 5% in 1985 to 26% in 2009 [2].
In the same year, the number of women living with HIV in
Canada was estimated to be 12,000, of whom approximately
2860 resided in the province of British Columbia (BC) [2].
The proportion of HIV in younger age groups is also higher
for women than for men [2, 3], suggesting that women are
contracting HIV at a younger age than men. The growing
feminization of the HIV epidemic means that more young
women of reproductive age will be living with HIV in
Canada.
HIV infection is associated with many women’s health
issues that may not be adequately addressed in HIV-specific
care [4, 5]. HIV-infected women are more likely than their
HIV-negative counterparts to have abnormal gynaecological
conditions, such as squamous intraepithelial lesions, cervical
cancer, and both bacterial and viral sexually transmitted
infections [6–11]. Psychological disorders such as depression
are also more prevalent among HIV-infected women than
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HIV-negative women, likely due to HIV-related stigma and
lack of social support [12, 13]. In addition, HIV-infected
women’s health focus changes as they go through diﬀerent
stages of life. Women of younger age may focus on menstrual
cycle disorders and family planning, while women aging with
HIV might need support managing menopause symptoms
and their heightened risk of osteoporosis [6]. The intro-
duction of highly active antiretroviral therapy (HAART) has
markedly prolonged the life expectancy and greatly increased
the reproductive expectations of HIV-infected women [6],
but HAART alone cannot address the multiple realms of
health impacted by one’s HIV status.
Women’s health care (WHC), including regular gynae-
cological care and counselling, has been shown to improve
women’s multiple health outcomes and should be provided
along with HIV-specific care to ensure a more integrated
and holistic care model centered on patients’ need [14–
16]. The World Health Organization (WHO) has proposed
a framework to strengthen the linkage between WHC and
HIV care at both policy and program levels [17]. However,
studies have shown an underutilization of women’s health
and gynaecological services among HIV-infected women in
the US and eastern Canada [18–20].
This study investigates the uptake of WHC among a
sample of harder-to-reach and treatment-experienced HIV-
infected women in BC, Canada and the factors associated
with utilization. Studies on the intersection betweenHIV and
WHC may provide suggestions for mitigating the wide range
of women’s health issues associated with HIV infection by
generating relevant program and policy recommendations.
2. Methods
2.1. Participants and Recruitment. We conducted our anal-
yses using data from the Longitudinal Investigations into
Supportive and Ancillary Health Services (LISA) study which
was specifically designed to recruit harder-to-reach popula-
tions living with HIV who have ever accessed antiretroviral
therapy (ART) in BC.
In BC, ART is distributed free of charge to all eligible peo-
ple living with HIV/AIDS through the Drug Treatment Pro-
gram (DTP) at the British Columbia Centre for Excellence
in HIV/AIDS (BC-CfE) [21]. Medications are distributed in
accordance with the guidelines set by the BC Therapeutic
Guideline Committee, which have remained consistent with
those from the International AIDS Society, USA between
1996 and at last revision in 2010 [22, 23]. Individuals are
enrolled in DTP when they are first prescribed ART by
their physicians. The physician must complete a drug request
form detailing baseline information, such as CD4 cell counts,
plasma HIV RNA levels, and past HIV-specific drug history
[21]. Patients on ART are then typically monitored by the
prescribing physicians at intervals no longer than three
months [24]. As of June 2012, approximately 5500 patients
are currently enrolled in the DTP [25].
In order to evaluate the impact of the social determi-
nants of health on the health care utilization and clinical
outcomes of harder-to-reach HIV-infected individuals who
have accessed ART in BC, the LISA study was established.
The LISA study consists of a comprehensive cross-sectional
survey, which collected data on participants’ sociodemo-
graphic information, service utilization, and quality of life.
Individuals who have ever enrolled in the DTP (or who had
initiated ART any time prior to the interview) and who were
at least 19 years of age at the time of interview were eligible to
participate in the LISA study. Between July 2007 and January
2010, all 9514 eligible participants enrolled in the DTP
were targeted through study information letters distributed
by physicians providing HIV care and at pharmacies when
patients refilled ART prescriptions. In addition to these
targeted recruitment strategies, participants were recruited
to participate in LISA through notices posted at HIV/AIDS
clinics and service organizations across the province and
via word-of-mouth advertising. A result of this convenience
sampling was an overrepresentation of individuals who were
already accessing HIV-related services. The study sought
to enroll 1000 individuals and to oversample particular
subpopulations (including women, people who inject drugs,
and people who identified themselves as aboriginal) to
provide suﬃcient power for subanalyses. Therefore, the LISA
cohort enrolled a nonprobability sample of DTP patients and
represented more marginalized populations with some level
of access to HIV-related services.
The LISA questionnaire, which was developed, reviewed,
and piloted with a team of researchers and a community
advisory board, was administered throughout BC by trained
interviewers at various clinics, HIV/AIDS service organiza-
tions, or by telephone. The questionnaire took approximately
60 minutes to complete, and a $20 honorarium was oﬀered
to each participant. The financial incentive resulted in an
oversampling of harder-to-reach populations.
For this analysis, inclusion was restricted to LISA par-
ticipants who identified themselves as females (versus male
or transgender) and who had HIV clinical data available
through the DTP.
Ethical approval for the LISA study was obtained from
the University of British Columbia/Providence Health Care,
Simon Fraser University, the University of Victoria, and the
Vancouver Coastal Health Research Ethics Boards.
2.2. Measures
2.2.1. Outcome Variable. The primary outcome variable
“WHC utilization” was assessed via self-report based on
responses to the statement “I have a physician who I see
regularly for women’s health care [e.g., pap smear, gynae-
cology].” Responses were dichotomized into “Yes, utilizes
WHC” (based on those who responded “definitely true” or
“somewhat true”) or “No, does not utilize WHC” (based on
those who responded “definitely false” or “somewhat false”).
A small number of women who responded “neither true nor
false” (n = 5) or who did not respond (n = 15) were excluded
from this analysis.
2.2.2. Explanatory Variables of Interest. The demographic
variables included age at interview, aboriginal ancestry (yes
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versus no), health authority (HA) (based on patient address),
rural residency (rural versus urban), and marital status (yes
versus no; yes defined as being legally married or common-
law).
Sociodemographic variables included education (high
school or greater versus others), current employment (yes
versus no), personal annual income (<$15, 000 versus
≥$15,000; including wages, salaries, net self-employment,
and any other income such as welfare), housing stability
(yes versus no; stable housing defined as living in a house
or apartment), and food security (yes versus no). Food
security was measured based on a modified version of the
Radimer/Cornell Questionnaire, and food insecurity was
defined as having at least one positive answer to any of the
13 questions [26, 27].
Psycho-social variables included HIV-related stigma,
perceived neighbourhood problems, perceived neighbour-
hood cohesion, and quality of life (QoL). HIV-related stigma
was measured using the validated HIV stigma scale ranging
from 0 to 100, with higher values corresponding to higher
HIV-related stigma [28]. Perceived neighbourhood problems
and perceived neighbourhood cohesion were assessed using
the scales developed by Ellaway et al., and the original
scales were transformed to range from 0 to 100, with higher
values indicating higher perceptions of more neighbourhood
problems or more neighbourhood cohesion [29]. The QoL
of participants was assessed using the validated HIV/AIDS-
targeted quality of life (HAT-QoL) instrument [30]. The
HAT-QoL scale has 9 dimensions: overall function, sexual
function, disclosure worries, health worries, financial wor-
ries, HIV mastery, life satisfaction, medical worries, and
provider trust. Each measure has a scale from 0 to 100, with
higher scores corresponding to better QoL.
Behavioural variables included alcohol use at time of
interview, illicit drug use at time of interview (illicit drugs
including cocaine, crack, heroin, speedball, crystal meth,
steroids, ecstasy, hallucinogens, GHB, and special K), injec-
tion of drugs at time of interview (drugs for injection
including cocaine, crack, heroin, speedball, and crystal
meth), sexual activity (active versus inactive; active defined as
having >0 sexual activities in last 6 months), condom use of
sexually active participants (yes versus no; yes being defined
as using condom 100% of the time during vaginal sex in the
last 6 months), sex trade history (yes versus no), pregnancy
intention (yes versus no), and number of births in life time.
Individual health status variables included history of sex-
ually transmitted infections (HPV, Chlamydia, gonorrhoea,
syphilis), abnormal Pap smear in the last 6 months (yes
versus no), and symptoms of depression (yes versus no).
The validated 10-item Center for Epidemiological Studies-
Depression (CES-D10) scale was used to assess symptoms
of depression, with scores of 10 or higher being defined as
having symptoms of depression [31].
HIV clinical variables were obtained from DTP and
included ART status at time of interview (yes versus no), CD4
count at time of interview (obtained from the most recent
test result prior to interview), plasma viral load (pVL, log
10/mL) at time of interview (obtained from the most recent
test result prior to interview), and VL suppression (defined
as having two consecutive tests of VL < 250 copies/mL 12
months prior to interview).
2.3. Statistical Analyses. The prevalence of WHC utilization
among LISA participants was estimated. Bivariate analyses
were then performed to examine associations between each
explanatory variable of interest and utilization ofWHC. Chi-
squared tests were used to compare categorical variables;
Wilcoxon’s rank sum test was used to compare continuous
variables. Marginally associated variables (P < 0.2) based
on the bivariate analyses were included in an exploratory
multivariable logistic regression model to identify indepen-
dent factors associated with WHC utilization. A backward
selection procedure using the Akaike Information Criterion
(AIC) was performed to select variables (P < 0.05) to be
included in the final model [32]. All analyses were conducted
using SAS 9.2 (SAS Inc., Cary, NC).
3. Results
A total of 1000 participants were recruited and interviewed
for the LISA study from July 2007 to January 2010; however,
only 917 were successfully linked to clinical data in the DTP,
as shown in Figure 1. Out of the 917 participants with clinical
data available, there were 231 women who were included
in this analysis. Overall, 179 (77%) of the HIV-infected,
treatment-experienced women reported utilizing WHC.
Table 1 describes the baseline characteristics of the
women included in this study. The median age was 41
years (interquartile range (IQR): 34–46). Half (49%) of
the participants reported being of aboriginal ancestry. The
geographical distribution of the participants was 60% in
Vancouver coastal HA, the more populated Pacific coast of
southwestern BC, 5% in Interior HA, BC’s southern interior
region including many rural communities, 4% in Northern
HA, northern BC consisting of a multitude of rural and First
Nations communities, 10% in Vancouver island HA, mainly
the islands to the west of Vancouver, and 21% in Fraser HA, a
populated region to the east of Vancouver. About half (47%)
of the participants had an education level of high school or
greater, 15% were currently employed and 72% reported an
annual income below $15,000. Housing was stable for 62%
of the women and 23% were food secure.
Table 1 also compares the characteristics of women who
utilized WHC and those who did not. The geographical
distribution was significantly diﬀerent (P < 0.01), with
a higher proportion living in Vancouver coastal HA (63%
versus 49%) and a lower proportion in Vancouver island HA
(6% versus 24%) for women who utilized WHC compared
with women who did not. Women who utilized WHC were
less likely to use illicit drugs (P < 0.01), more likely to be
employed (P = 0.04), less likely to have an annual income
<$15,000 (P < 0.01), more likely to have stable housing
(P = 0.02), and more likely to have a higher score for
perceived neighbourhood cohesion (P = 0.02) and provider
trust (P < 0.01). Although women who utilized WHC
had higher percentage of ART use at the time of interview
and higher rate of VL suppression, none of the HIV-related
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- Lack of clinical data (n = 83)
- Did not identify themselves as women (n = 666)
Women included in this study  
(n = 231)
- Missing response for outcome variable (n = 20)
Women participants in LISA study 
(n = 251)
LISA participants with clinical data 
(n = 917)
Participants recruited for LISA study 
HIV-positive individuals on ART eligible to 
participate in LISA study 
(n = 9514)
(n = 1000)
Figure 1: Selection of study subjects from the original LISA cohort.
clinical variables showed significant diﬀerences between the
two comparison groups.
Table 2 displays the results of the multivariable logis-
tic regression model and shows that the adjusted odds
ratios were consistent with the unadjusted odds ratios. The
adjusted odds of WHC utilization among participants were
88% lower in Vancouver island HA compared with Van-
couver coastal HA (AOR = 0.12, 95 CI (0.04–0.37)), 58%
lower among illicit drug users compared with nondrug users
(AOR = 0.42, 95 CI (0.19, 0.92)), and 86% lower for those
with income <$15,000 compared with those with income ≥
$15,000 (AOR = 0.14, 95 CI (0.04, 0.54)). A one-unit decrease
in the provider trust scale was associated with a 3% decrease
in the adjusted odds of WHC utilization (AOR = 0.97, 95 CI
(0.95, 0.99)).
4. Discussion
Our results demonstrate the existence of a health service gap
along geographical and social axes for harder-to-reach HIV-
infected women who have accessed ART in BC. We found
that 77% of the women in the LISA cohort used WHC. This
study is among the first to assess the prevalence of WHC uti-
lization among HIV-infected women as the previous litera-
ture documented utilization of gynaecological service only.
This study shows that poorer socioeconomic status is
associated with women’s ability to access WHC, despite
a context that theoretically provides universal health care.
Income-related inequalities in health care utilization have
been well documented in countries with universal health care
systems [33]. In Canada, lower income has been shown to
be associated with less contact with general practitioners and
specialists and decreased use of surgical day care [34, 35].
Several qualitative studies have examined the barriers to
health care experienced by low-income Canadians and found
some of the major barriers to be transportation cost, lack of
childcare, and a lack of integration of health services [36, 37].
The socioeconomic inequality in WHC utilization demon-
strated in this study points to the necessity of providing
health services tailored to the needs of low-income women,
which may include outreach and providing transportation
reimbursement, food, and free childcare during clinic visits.
Furthermore, while struggling to meet their basic needs, low-
income women might have other competing demands in
life such as food and housing. The fact that stable housing
and employment were marginally associated with WHC uti-
lization in this study speaks to the need for socio-economic
policy reform in BC that addresses structural determinants
of health such as housing aﬀordability and unemployment.
Utilization of WHC was negatively associated with illicit
drug use. This is consistent with findings from previous stud-
ies investigating the relationship between illicit drug use and
gynaecological service utilization [38, 39]. It is worth noting
that drug injection was not associated with the outcome in
this study. This may indicate that the method of drug use
does not innately influence access to WHC, but rather, that
stigma and social barriers exist for all illicit drug users
[37, 40, 41]. The exact pathways linking illicit drug use and
WHC utilization are not clear and require further qualitative
studies.
Lower provider trust was associated with a lack of WHC
utilization in this study. Trust in physicians has long been
identified as a determining factor for patient’s utilization of
health care services [42, 43], but this study has revealed
a more specific relationship, namely, between trust in the
physician who provides regular HIV care and women’s utili-
zation of WHC. This indicates the pivotal role of HIV care
physicians in influencing HIV-infected women’s health seek-
ing behaviour. This cohort had a high score of provider trust,
with amedian of 92 for womenwho utilizedWHC and 83 for
women who did not. Therefore, women in the cohort were
generally satisfied with theHIV care they received. In order to
further improve physician trust, evidence suggests that
women should be provided with a safe, nonjudgemental cli-
nical environment and an option of seeing a female care
provider who could improve patient-physician relationship
by making women feel safer and more understood, especially
when gynaecological care is involved [37].
The geographical variation in WHC utilization may re-
flect the inequity of health service provision in rural versus
urban areas of BC, where larger communities in Vancouver
coastal HA generally have more comprehensive and easily
accessible health services than smaller communities in Van-
couver island HA [44]. However, due to the large proportion
of missing data for participants’ rural residency status, the
exact reasons behind this geographical variation could not
be determined, and further studies are warranted.
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All (n = 231) Yes (n = 179) No (n = 52)
Demographic variables
Age at interview (years) (median (IQR)) 41 (34–46) 41 (34–46) 41 (36–46) 0.70
Aboriginal ancestry (% Y) 114 (49%) 87 (49%) 27 (52%) 0.67
Health authority (HA) <0.01
(i) Vancouver coastal HA 136 (60%) 111 (63%) 25 (49%)
(ii) Interior HA 11 (5%) 10 (6%) 1 (2%)
(iii) Northern HA 10 (4%) 7 (4%) 3 (6%)
(iv) Vancouver island HA 22 (10%) 10 (6%) 12 (24%)
(v) Fraser HA 48 (21%) 38 (22%) 10 (20%)
Rural residency (% rural)∗ 3 (2%) 3 (2%) 0 (0%) 0.99
Marital status (% Y) 42 (18%) 29 (16%) 13 (25%) 0.15
Sociodemographic variables
High school or greater (% Y) 108 (47%) 87 (49%) 21 (40%) 0.30
Employment (% Y) 34 (15%) 31 (17%) 3 (6%) 0.04
Annual income < $15,000 (% Y) 166 (72%) 119 (66%) 47 (92%) <0.01
Housing stability (% Y) 143 (62%) 118 (66%) 25 (48%) 0.02
Food security (% Y) 54 (23%) 44 (25%) 10 (19%) 0.41
Psychosocial variables
HIV-related stigma (scale, median (IQR)) 53 (38–65) 53 (38–68) 50 (38–65) 0.63
Perceived neighbourhood problems (scale, median (IQR)) 35 (15–62) 35 (15–62) 35 (19–62) 0.98
Perceived neighbourhood cohesion (scale, median (IQR)) 56 (43–66) 56 (44–69) 51 (35–62) 0.02
Quality of life (scale, median (IQR))
(i) Overall function 43 (29–64) 43 (25–64) 43 (32–64) 0.88
(ii) Life satisfaction 69 (50–75) 69 (53–78) 63 (47–75) 0.07
(iii) Health worry 45 (30–65) 45 (30–65) 45 (25–65) 0.79
(iv) Financial worry 38 (19–63) 38 (19–63) 38 (25–56) 0.50
(v) Medical worry 69 (56–75) 69 (56–75) 63 (56–75) 0.10
(vi) Disclosure worry 50 (35–65) 50 (35–65) 55 (35–65) 0.67
(vii) HIV Mastery 50 (42–75) 58 (42–75) 50 (42–75) 0.79
(viii) Provider trust 92 (75–100) 92 (75–100) 83 (75–100) <0.01
(ix) Sexual function 50 (42–67) 50 (42–67) 50 (42–58) 0.58
Behavioural variables
Alcohol use at time of interview (% Y) 105 (48%) 79 (47%) 26 (52%) 0.54
Illicit drug use at time of interview (% Y) 123 (53%) 85 (48%) 38 (73%) <0.01
Injection of drugs at time of interview (% Y) 53 (23%) 37 (21%) 16 (31%) 0.13
Sexually active in last 6 months (% Y) 125 (54%) 100 (56%) 25 (48%) 0.32
Condom use of sexually active participants∗∗ (% Y) 46 (40%) 36 (40%) 10 (42%) 0.85
Sex trade history∗∗∗ (% Y) 71 (57%) 52 (55%) 19 (66%) 0.30
Pregnancy intention (% Y) 32 (14%) 26 (15%) 6 (12%) 0.58
Number of births in life time (median (IQR)) 2 (1–3) 2 (1–4) 2 (1–3) 0.43
Individual health status variables
Ever diagnosed with HPV (% Y) 18 (8%) 15 (8%) 3 (6%) 0.53
Ever diagnosed with chlamydia (% Y) 48 (21%) 33 (18%) 15 (29%) 0.10
Ever diagnosed with gonorrhea (% Y) 38 (16%) 28 (16%) 10 (19%) 0.54
Ever diagnosed with syphilis (% Y) 22 (10%) 15 (8%) 7 (13%) 0.27
Abnormal Pap smear in last 6 months (% Y)∗∗∗∗ 34 (17%) 28 (17%) 6 (15%) 0.75
Symptoms of depression (% Y) 156 (68%) 121 (68%) 35 (67%) 0.97




All (n = 231) Yes (n = 179) No (n = 52)
HIV clinical variables
ART status at time of interview (% Y) 177 (77%) 141 (79%) 36 (69%) 0.15
CD4 count at time of interview (median (IQR)) 300 (170–470) 290 (170–470) 310 (175–475) 0.85
pVL (log 10) at time of interview (median (IQR)) 1.7 (1.5–3.1) 1.7 (1.5–3.1) 1.7 (1.5–3.0) 0.46
VL suppression (% Y) 140 (61%) 111 (62%) 29 (56%) 0.42
∗30% of the data are missing (n = 162).
∗∗50% of the data are missing (n = 116).
∗∗∗46% of the data are missing (n = 125).
∗∗∗∗only participants who answered “yes” or “no” were included in the denominator.
Table 2: Multivariate analysis of factors associated with women’s health care (WHC) utilization among HIV-infected women in the LISA
cohort.
Unadjusted Adjusted
Variable odds ratio (OR) P value odds ratio (AOR) P value
(95% CI) (95% CI)
Health authority (HA) <0.01 <0.01
Vancouver coastal HA 1.00 (—) 1.00 (—)
Fraser HA 0.86 (0.38–1.95) 0.52 (0.21–1.29)
Interior HA 2.25 (0.28–18.40) 1.78 (0.19–16.79)
Northern HA 0.53 (0.13–2.18) 0.43 (0.09–2.07)
Vancouver island HA 0.19 (0.07–0.48) 0.12 (0.04–0.37)
Annual income <0.01 <0.01
≥C$15,000 1.00 (—) 1.00 (—)
<C$15,000 0.17 (0.06–0.49) 0.14 (0.04–0.54)
Illicit drug use <0.01 0.03
No 1.00 (—) 1.00 (—)
Yes 0.34 (0.17–0.66) 0.42 (0.19–0.92)
Provider trust (QoL scale) 0.96 (0.94–0.98) 0.03 0.97 (0.95–0.99) 0.03
HIV-related clinical variables did not vary by WHC
utilization status, suggesting that all women in this study
responded similarly to HIV-specific treatment. The lack of
association between WHC and HIV clinical variables reflects
a lack of integration between WHC and HIV care and a
deficiency in women’s holistic care in BC. Centralizing and
streamlining WHC with HIV-specific care should be empha-
sized to avoid unnecessary shuﬄing of patients within the
health care system. WHC could be tailored to low-income
women’s financial need by providing transportation reim-
bursement and free childcare and could increase patient’s
provider trust by oﬀering a safe, nonjudgemental multidis-
ciplinary environment and the option of seeing a female
care provider. These suggestions echo the best practices in
promoting HIV-infected women’s health [45–47]. Oak Tree
Clinic (OTC) located in Vancouver has been a pioneer
in implementing women-centered care for HIV-infected
women in BC. The clinic is a provincial resource for HIV-
infected women and children, with HIV care, obstetrical and
gynaecological care, dietary care, and social support all amal-
gamated within one facility [48]. The fact that a quarter of
the women in this study were recruited from the OTC could
explain the relatively high prevalence of WHC utilization
among study participants.
An ad hoc analysis was done comparingWHC utilization
between women who accessed care at OTC and women who
did not. As shown in Supplemental Table 1 available online
at doi:10.1155/2012/560361, WHC utilization and access to
OTC was highly associated (P < 0.01), and women who
accessed OTC were significantly more likely to report WHC
utilization than womenwho did not access OTC. This may be
related to the fact that health care providers at the OTC are
highly sensitized to the importance of WHC and incorporate
WHC to routine HIV care. The outreach social workers
and nurses, as well as free food and child care at the OTC,
also help bring in harder-to-reach women, such as women
who inject drugs and who have low income. Furthermore,
OTC provides a safe women’s majority (75%) environment
to help build trust, and the clinicians have developed long-
term relationship with the patients. The multidisciplinary
team works to increase women’s engagement and ability to
deal with the HIV challenges. This ad hoc analysis provided
strong evidence that women-centered multidisciplinary ser-
vice integration could eﬀectively encourage WHC utilization
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and promote health among HIV-infected women, especially
the harder-to-reach women. As the next step, studies could
be designed to more thoroughly evaluate OTC’s model of
care.
Readers should be cautious when interpreting our find-
ings to the general population of women infected with HIV
in the province. Oversampling of injection drug users and
aboriginal people means that women in this cohort may
encounter more social vulnerability. The financial incentives
provided to all LISA study participants might have intro-
duced volunteer bias, where women in need of financial gain,
particularly those who reside in the impoverished downtown
east side of Vancouver, were overrepresented. As LISA study
participants have accessed HIV treatment and were recruited
through physicians, clinics, and AIDS service organizations,
those interviewed were already connected to care in some
degree. Therefore, our sample does not include those indi-
viduals who are not able to access care and may face several
structural barriers to care and thus may not represent the
most marginalized people living with HIV in BC. Second, the
variables used in this study were self-reported and, therefore,
subject to recall bias and social desirability bias. Future
studies could use physician or hospital records to objectively
assess WHC utilization among HIV-infected women who
have accessed ART. Third, the definition of WHC might vary
among study participants. Somemight interpret it as services
including a Pap smear, while others might consider it a full
range of services tailored towards women. Future studies
could divide this broadermeasure ofWHC intomore specific
type of services. Fourth, automated backward selection pro-
cedure ran the risk of eliminating variables that are meaning-
fully associated with the outcome solely based on statistical
significance, but it provided an objective way of model selec-
tion. Lastly, the cross-sectional design of this study means
that causality cannot be inferred in the relationship between
WHC utilization and the covariates. However, previous
qualitative studies have revealed some of the social path-
ways linking WHC utilization with income and provider
trust, rendering policy recommendations more relevant and
persuasive.
In conclusion, our findings suggest that there is a health
service gap for harder-to-reach HIV-infected women who
have accessed ART in BC. Improvements could be made by
enhancing the integration between HIV-specific care and
WHC and providing women-centered health services. Socio-
economic policy reforms are also needed to address the struc-
tural inequalities in health.
Acknowledgments
The authors would like to thank participants from the LISA
cohort for their willingness to share sensitive information to
support research activity and community development. They
also thank other members from the LISA study team who
provided support in various aspects of the study.
References
[1] UNAIDS, “Global report: UNAIDS report on the global AIDS
epidemic 2010,” UNAIDS/10.11E —JC1958E, 2010.
[2] PHAC, HIV and AIDS in Canada—Surveillance Report to
December 31, 2009. 2010, HP37-2/2009.
[3] C. Archibald andM. Gatali, “Women andHIV,” BMCWomens
Health vol. 4, S27, 2004.
[4] P. Tsasis, “HIV/AIDS challenges the normative model of
healthcare delivery in Canada,” Health Services Management
Research, vol. 14, no. 1, pp. 55–61, 2001.
[5] K. Church and S. Lewin, “Delivering integrated hiv services:
time for a client-centred approach to meet the sexual and re-
productive health needs of people living with hiv?” AIDS, vol.
24, no. 2, pp. 189–193, 2010.
[6] H. E. Cejtin, “Gynecologic issues in the HIV-infected women,”
Infectious Disease Clinics of North America, vol. 22, no. 4, pp.
709–739, 2008.
[7] D. H. Watts, C. Spino, L. Zaborski, D. Katzenstein, S. Ham-
mer, and C. Benson, “Comparison of gynecologic history and
laboratory results in HIV-positive women with CD4+ lym-
phocyte counts between 200 and 500 cells/µl and below 100
cells/µl,” Journal of Acquired Immune Deficiency Syndromes and
Human Retrovirology, vol. 20, no. 5, pp. 455–462, 1999.
[8] A. Duerr, B. Kieke, D. Warren et al., “Human papillomavirus-
associated cervical cytologic abnormalities among women
with or at risk of infection with human immunodeficiency
virus,” American Journal of Obstetrics & Gynecology, vol. 184,
no. 4, pp. 584–590, 2001.
[9] L. S. Massad, L. Ahdieh, L. Benning et al., “Evolution of cer-
vical abnormalities among women with HIV-1: evidence from
surveillance cytology in the Women’s Interagency HIV Study,”
Journal of Acquired Immune Deficiency Syndromes, vol. 27, no.
5, pp. 432–442, 2001.
[10] M. Frisch, R. J. Biggar, and J. J. Goedert, “Human papillo-
mavirus-associated cancers in patients with human immun-
odeficiency virus infection and acquired immunodeficiency
syndrome,” Journal of the National Cancer Institute, vol. 92, no.
18, pp. 1500–1510, 2000.
[11] G. M. Cliﬀord, J. Polesel, M. Rickenbach et al., “Cancer risk in
the Swiss HIV cohort study: associations with immunode-
ficiency, smoking, and highly active antiretroviral therapy,”
Journal of the National Cancer Institute, vol. 97, no. 6, pp. 425–
432, 2005.
[12] B. Owe-Larsson, L. Sa¨ll, E. Salamon, and C. Allgulander, “HIV
infection and psychiatric illness,” African Journal of Psychiatry,
vol. 12, no. 2, pp. 115–128, 2009.
[13] L. C. Simbayi, S. Kalichman, A. Strebel, A. Cloete, N. Henda,
and A. Mqeketo, “Internalized stigma, discrimination, and de-
pression among men and women living with HIV/AIDS in
Cape Town, South Africa,” Social Science & Medicine, vol. 64,
no. 9, pp. 1823–1831, 2007.
[14] D. S. Guzick, “Eﬃcacy of screening for cervical cancer: a re-
view,” American Journal of Public Health, vol. 68, no. 2, pp.
125–134, 1978.
[15] M. Magnus, N. Schmidt, K. Kirkhart et al., “Association bet-
ween ancillary services and clinical and behavioral outcomes
among HIV-infected women,” AIDS Patient Care and STDs,
vol. 15, no. 3, pp. 137–145, 2001.
[16] A. A. Krabbendam, B. Kuijper, I. N. Wolﬀers, and R. Drew,
“The impact of counselling on HIV-infected women in Zim-
babwe,” AIDS Care, vol. 10, supplement 1, pp. S25–S37, 1998.
8 AIDS Research and Treatment
[17] WHO, “HIV/AIDS Department, Sexual and reproductive
health and HIV/AIDS: a framework for priority linkages,”
2005, WHO/HIV/2005.05.
[18] M. A. Tello, M. Jenckes, J. Gaver, J. R. Anderson, R. D. Moore,
and G. Chander, “Barriers to recommended gynecologic care
in an urban United States HIV clinic,” Journal of Women’s
Health, vol. 19, no. 8, pp. 1511–1518, 2010.
[19] J. L. Logan, M. Q. Khambaty, K. M. D’Souza, and L. J.
Menezes, “Cervical cancer screening among HIV-infected
women in a health department setting,” AIDS Patient Care and
STDs, vol. 24, no. 8, pp. 471–475, 2010.
[20] P. Leece, C. Kendall, C. Touchie, K. Pottie, J. B. Angel, and
J. Jaﬀey, “Cervical cancer screening among HIV-positive
women: retrospective cohort study from a tertiary care HIV
clinic,” Canadian Family Physician, vol. 56, no. 12, pp. e425–
e431, 2010.
[21] R. S. Hogg, K. V. Heath, B. Yip et al., “Improved survival
amongHIV-infected individuals following initiation of antire-
troviral therapy,” The Journal of the American Medical Associa-
tion, vol. 279, no. 6, pp. 450–454, 1998.
[22] M. A. Thompson, J. A. Aberg, P. Cahn et al., “Antiretroviral
treatment of adult HIV infection: 2010 recommendations of
the International AIDS Society-USA panel,” The Journal of the
American Medical Association, vol. 304, no. 3, pp. 321–333,
2010.
[23] C. C. J. Carpenter, M. A. Fischl, S. M. Hammer et al., “Anti-
retroviral therapy for HIV infection in 1998: updated recom-
mendations of the International AIDS Society-USA panel,”
The Journal of the American Medical Association, vol. 280, no.
1, pp. 78–86, 1998.
[24] S. Parashar, A. K. Palmer, N. O’Brien et al., “Sticking to
it: the eﬀect of maximally assisted therapy on antiretroviral
treatment adherence among individuals living with HIV who
are unstably housed,” AIDS and Behavior, vol. 15, no. 8, pp.
1612–1622, 2011.
[25] BCCfE, “Drug Treatment Program,” 2012, http://www.cfenet
.ubc.ca/drug-treatment-program.
[26] A. Kendall, C. M. Olson, and E. A. Frongillo, “Validation of
the Radimer/Cornell measures of hunger and food insecurity,”
The Journal of Nutrition, vol. 125, no. 11, pp. 2793–2801, 1995.
[27] K. L. Radimer, C. M. Olson, and C. C. Campbell, “Develop-
ment of indicators to assess hunger,” The Journal of Nutrition,
vol. 120, supplement 11, pp. 1544–1548, 1990.
[28] B. E. Berger, C. E. Ferrans, and F. R. Lashley, “Measuring
stigma in people with HIV: psychometric assessment of the
HIV stigma scale,” Research in Nursing & Health, vol. 24, no.
6, pp. 518–529, 2001.
[29] A. Ellaway, S. Macintyre, and A. Kearns, “Perceptions of place
and health in socially contrasting neighbourhoods,” Urban
Studies, vol. 38, no. 12, pp. 2299–2316, 2001.
[30] W. C. Holmes and J. A. Shea, “A new HIV/AIDS targeted qual-
ity of life (HAT-QoL) instrument: development, reliability,
and validity,” Medical Care, vol. 36, no. 2, pp. 138–154, 1998.
[31] E. M. Andresen, J. A. Malmgren, W. B. Carter, and D. L.
Patrick, “Screening for depression in well older adults: eval-
uation of a short form of the CES-D,” American Journal of
Preventive Medicine, vol. 10, no. 2, pp. 77–84, 1994.
[32] J. M. Lachin, Biostatistical Methods: The Assessment of Relative
Risks, John Wiley & Sons, New York, NY, USA, 2000.
[33] E. Van Doorslaer, C. Masseria, and X. Koolman, “Inequalities
in access to medical care by income in developed countries,”
Canadian Medical Association Journal, vol. 174, no. 2, pp. 177–
183, 2006.
[34] Y. Asada and G. Kephart, “Equity in health services use and
intensity of use in Canada,” BMCHealth Services Research, vol.
7, article 41, 2007.
[35] K. M. McGrail, “Income-related inequities: cross-sectional
analyses of the use of medicare sorvices in British Columbia
in 1992 and 2002,” Open Medicine, vol. 2, no. 4, pp. e91–e98,
2008.
[36] D. L. Williamson, M. J. Stewart, K. Hayward et al., “Low-
income Canadians’ experiences with health-related services:
implications for health care reform,” Health Policy, vol. 76, no.
1, pp. 106–121, 2006.
[37] Leah M. Palmer, “Meeting the health and health care needs of
low-income women,” Open Access Dissertations and Theses
2006, Paper 4885.
[38] M. A. Tello, H. C. Yeh, J. M. Keller, M. C. Beach, J. R.
Anderson, and R. D. Moore, “HIV women’s health: a study
of gynecological healthcare service utilization in a U.S. urban
clinic population,” Journal of Women’s Health, vol. 17, no. 10,
pp. 1609–1614, 2008.
[39] H. E. Cejtin, E. Komaroﬀ, L. S. Massad et al., “Adherence to
colposcopy among women with HIV infection,” Journal of
Acquired Immune Deficiency Syndromes and Human Retrovi-
rology, vol. 22, no. 3, pp. 247–252, 1999.
[40] B. Roe, C. Beynon, L. Pickering, and P. Duﬀy, “Experiences of
drug use and ageing: health, quality of life, relationship and
service implications,” Journal of Advanced Nursing, vol. 66, no.
9, pp. 1968–1979, 2010.
[41] J. A. Cunningham, L. C. Sobell, M. B. Sobell, S. Agrawal, and
T. Toneatto, “Barriers to treatment: why alcohol and drug
abusers delay or never seek treatment,” Addictive Behaviors,
vol. 18, no. 3, pp. 347–353, 1993.
[42] J. L. Graham, T. P. Giordano, R.M. Grimes, J. Slomka,M. Ross,
and L. Y. Hwang, “Influence of trust on HIV diagnosis and
care practices: a literature review,” Journal of the International
Association of Physicians in AIDS Care, vol. 9, no. 6, pp. 346–
352, 2010.
[43] S. Ostertag, B. R. E. Wright, R. S. Broadhead, and F. L. Altice,
“Trust and other characteristics associated with health care
utilization by injection drug users,” Journal of Drug Issues, vol.
36, no. 4, pp. 953–974, 2006.
[44] D. Cloutier-Fisher, M. J. Penning, C. Zheng, and E. B. F.
Druyts, “The devil is in the details: trends in avoidable hospita-
lization rates by geography in British Columbia, 1990–2000,”
BMC Health Services Research, vol. 6, article 104, 2006.
[45] P. Kissinger, R. Clark, J. Rice, H. Kutzen, A. Morse, and W.
Brandon, “Evaluation of a program to remove barriers to
public health care for women with HIV infection,” Southern
Medical Journal, vol. 88, no. 11, pp. 1121–1125, 1995.
[46] E. Abel, L. Hopson, and C. Delville, “Health promotion for
women with human immunodeficiency virus or acquired im-
munodeficiency syndrome,” Journal of the American Academy
of Nurse Practitioners, vol. 18, no. 11, pp. 534–543, 2006.
[47] L. Myer, M. Rabkin, E. J. Abrams, A. Rosenfield, andW.M. El-
Sadr, “Focus on women: linking HIV care and treatment with
reproductive health services in the MTCT-plus initiative,” Re-
productive Health Matters, vol. 13, no. 25, pp. 136–146, 2005.
[48] BC Women’s Hospital & Health Centre and Oak Tree
Cilinic Services, 2012, http://www.bcwomens.ca/Services/
HealthServices/OakTreeClinic/Services.htm.




Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013
The Scientific 
World Journal
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
PPAR
Resea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Computational and 
Mathematical Methods 
in Medicine
ISRN 
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Clinical &
Developmental
Immunology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
ISRN 
Biomarkers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
MEDIATORS
INFLAMMATION
of
